OCS
Oculis Holding AG

74
Loading...
Loading...
News
all
press releases
Oculis Holding AG (OCS) Reports Q2 Loss, Beats Revenue Estimates
Oculis Holding AG (OCS) delivered earnings and revenue surprises of -11.32% and +28.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
More News
News Placeholder
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Beats Revenue Estimates
Adherex Technologies (FENC) delivered earnings and revenue surprises of -83.33% and +1.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +62.50% and +4,225.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio (GBIO) delivered earnings and revenue surprises of -11.43% and -51.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +100.00% and +2.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
Lexicon (LXRX) delivered earnings and revenue surprises of +112.50% and +344.78%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
chainwire·4mo ago
News Placeholder
Oculis Holding Shows Strong Asset and Equity Growth
Oculis Holding (OCS) has released an update. Oculis Holding AG's unaudited financial statements indicate an increase in total assets from CHF 114.3...
TipRanks Financial Blog·1y ago
News Placeholder
Oculis to Participate at Upcoming April Investor Conferences
ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) ( Oculis ), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Globe Newswire·1y ago

Latest OCS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.